Non-interventional cardiologists' perspectives on the role of pharmacogenomic testing in cardiovascular medicine
- PMID: 30543145
- DOI: 10.2217/pme-2018-0099
Non-interventional cardiologists' perspectives on the role of pharmacogenomic testing in cardiovascular medicine
Abstract
Aim: To evaluate factors influencing cardiologists' perspectives about pharmacogenomic (PGx) testing in clinical practice.
Patients & methods: Semistructured interviews with practicing cardiologists were qualitatively analyzed to identify common themes.
Results: Five themes were identified among 16 cardiologists from four specialties (n = 5 general cardiology, n = 3 electrophysiology, n = 2 adult congenital and n = 6 heart failure/transplant): cardiologists' knowledge and needs, perceived clinical validity and utility of PGx testing, dissemination and management of PGx results, patient-related considerations and incidental findings.
Conclusion: Lack of evidence was considered by many cardiologists to be a major barrier hindering the use of PGx testing. However, they would consider adopting PGx if they were provided additional education, ongoing support and evidence supporting the clinical utility of PGx testing in cardiovascular medicine.
Keywords: cardiologist; cardiology; clinical implementation; personalized medicine; pharmacogenetic; pharmacogenomic; qualitative research.
Similar articles
-
Interventional cardiologists' attitudes towards pharmacogenetic testing and impact on antiplatelet prescribing decisions.Per Med. 2022 Jan;19(1):41-49. doi: 10.2217/pme-2021-0088. Epub 2021 Dec 9. Per Med. 2022. PMID: 34881641
-
Primary care physician experiences with integrated pharmacogenomic testing in a community health system.Per Med. 2017 Sep;14(5):389-400. doi: 10.2217/pme-2017-0036. Epub 2017 Aug 2. Per Med. 2017. PMID: 29754567
-
Stakeholder perspectives of the clinical utility of pharmacogenomic testing in solid organ transplantation.Pharmacogenomics. 2019 Dec;20(18):1291-1302. doi: 10.2217/pgs-2019-0129. Epub 2019 Nov 22. Pharmacogenomics. 2019. PMID: 31755847
-
Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline.Expert Opin Drug Metab Toxicol. 2019 Sep;15(9):751-765. doi: 10.1080/17425255.2019.1658742. Epub 2019 Sep 12. Expert Opin Drug Metab Toxicol. 2019. PMID: 31512953 Review.
-
Pharmacogenetic Panel Testing: A Review of Current Practice and Potential for Clinical Implementation.Annu Rev Pharmacol Toxicol. 2025 Jan;65(1):91-109. doi: 10.1146/annurev-pharmtox-061724-080935. Epub 2024 Dec 17. Annu Rev Pharmacol Toxicol. 2025. PMID: 39348848 Review.
Cited by
-
A qualitative approach to assess the opinion of physicians about the challenges and prospects of pharmacogenomic testing implementation in clinical practice in Greece.Hum Genomics. 2024 Jul 19;18(1):82. doi: 10.1186/s40246-024-00648-y. Hum Genomics. 2024. PMID: 39030587 Free PMC article.
-
Preparing Medical Specialists to Practice Genomic Medicine: Education an Essential Part of a Broader Strategy.Front Genet. 2019 Sep 11;10:789. doi: 10.3389/fgene.2019.00789. eCollection 2019. Front Genet. 2019. PMID: 31572433 Free PMC article. Review.
-
Knowledge and attitudes on implementing cardiovascular pharmacogenomic testing.Clin Transl Sci. 2024 Mar;17(3):e13737. doi: 10.1111/cts.13737. Clin Transl Sci. 2024. PMID: 38421234 Free PMC article.
-
Comfort with Pharmacogenetic Testing Amongst Pediatric Oncology Providers and Their Patients.J Pediatr Hematol Oncol Nurs. 2022 May-Jun;39(3):168-177. doi: 10.1177/10434542211055999. J Pediatr Hematol Oncol Nurs. 2022. PMID: 35467433 Free PMC article.
-
Development of the pharmacogenomics and genomics literacy framework for pharmacists.Hum Genomics. 2021 Oct 16;15(1):62. doi: 10.1186/s40246-021-00361-0. Hum Genomics. 2021. PMID: 34656176 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources